Spago Nanomedical
0,334 SEK -14,8%Vær den første som følger denne virksomhed
Spago Nanomedical conducts research and development in cancer diagnostics. The company conducts various development projects based on its proprietary nanomaterials whose potential is found in making tumours visible, and enabling internal radiation therapy of cancer. The company was founded in 2007 and is based in Lund.
Omsætning
-
EBIT %
-
P/E
-
Udbytteafkast, %
-
Kursmål
-
Anbefaling
-
Opdateret
-
First North Stockholm
SPAGO
Daglig lav / høj pris
0,322 / 0,388
SEK
Markedsværdi
116,3 mio. SEK
Aktieomsætning
165,51 t SEK
Volumen
480 t
Finanskalender
Delårsrapport
21.08.2024
Delårsrapport
06.11.2024
Større aktionærerKilde: Millistream Market Data AB
Ejer | Kapital | Stemmer |
---|---|---|
Peter Lindell | 40,5 % | 40,5 % |
Mikael Lönn | 8,5 % | 8,5 % |
Premium
This content is for our Premium customers only.
ViserAlle indholdstyper
Spago Nanomedical announces outcome of the exercise of warrants series TO12
Spago Nanomedical receives declarations of intent from the largest owner, board and management team regarding the exercise of TO12
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools